Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

NCT04520451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin G4 Related Disease

Interventions

DRUG: rilzabrutinib
DRUG: Glucocorticoids

Sponsor

Principia Biopharma, a Sanofi Company

Collaborators

[object Object]